Karyopharm Files for Chapter 11 Bankruptcy
The Massachusetts drugmaker filed for bankruptcy protection as its cash runway narrowed and its lead drug faced clinical and regulatory setbacks.
Updated on Nov. 2, 2026 in Healthcare
Karyopharm Therapeutics, a Massachusetts-based drugmaker, filed for Chapter 11 bankruptcy, and Ayrmid was named lead bidder in a court-supervised sale of its assets. The company said it had secured commitments for up to $55 million in debtor-in-possession financing from existing lenders.
Why it matters
Karyopharm's financial troubles came to a head when second-quarter earnings showed it was losing cash despite revenue from Xpovio, its main product. The filing follows a series of setbacks in Xpovio's clinical trials and regulatory status.
Xpovio sales were $30.8 million in the second quarter of 2026, up from $29.7 million a year earlier, within an annual range of $112 million to $115 million since 2023. Karyopharm cut 20% of its staff in 2023 and another 20% last year, while its stock fell 68% after an endometrial cancer trial failure, and the terms of Ayrmid's bid remain undisclosed.
The players
Karyopharm Therapeutics
A Massachusetts-based drugmaker whose main product is the cancer therapy Xpovio, which has faced repeated clinical and regulatory setbacks.
Ayrmid
An Irish drug company with two FDA-approved products that was named lead bidder in the court-supervised sale of Karyopharm's assets.
The details
Karyopharm's cash runway was said to cover only about another month when it sought court protection. Ayrmid, an Irish company that currently has two FDA-approved products, was named lead bidder in the proposed sale, and the transaction is expected to close in the first quarter of 2027.
Timeline
March: Xpovio met only one of two primary endpoints in a phase 3 myelofibrosis trial.
May: The FDA rescinded Xpovio's accelerated approval in relapsed or refractory DLBCL.
July: A second Xpovio phase 3 trial in endometrial cancer missed its progression-free survival endpoint.
August: Second-quarter earnings showed Karyopharm was burning cash.
November 2, 2026: Karyopharm filed for Chapter 11 and Ayrmid's lead bid was announced.
Market Landscape
Karyopharm's collapse illustrates how single-product oncology companies depend on the FDA's accelerated approval pathway, and the May rescission of Xpovio's DLBCL indication removed a key revenue support. The case shows how narrow revenue bases leave smaller drugmakers vulnerable to a single failed trial or regulatory reversal.
Patients currently relying on Xpovio should watch for how the sale affects supply and availability of the drug during the bankruptcy process. Shareholders face significant uncertainty, as the stock has already fallen sharply and the terms of the Ayrmid deal have not been disclosed.
The takeaway
Single-product biotech companies are highly exposed to clinical and regulatory setbacks, and Karyopharm's case shows how quickly a narrow revenue base can unravel. Readers tracking drug pipelines should watch how court-supervised sales handle competing bids.
What happens next
The court's review of the proposed bidding structure will determine whether other parties can submit competing proposals before the expected first-quarter 2027 closing.
Further reading
For more on the state's drug developers, see Healthcare coverage across Massachusetts.
